Trial Profile
A Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of MT-8554 on the Frequency and Severity of Vasomotor Symptoms in Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 May 2023
Price :
$35
*
At a glance
- Drugs Elismetrep (Primary)
- Indications Hot flashes; Vasomotor symptoms
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma America
- 03 Oct 2020 Results assessing the efficacy and safety of elismetrep in postmenopausal women with VMS presented at the North American Menopause Society 2020 Annual Meeting
- 20 Nov 2018 Status changed from active, no longer recruiting to completed.
- 25 Jul 2018 Status changed from recruiting to active, no longer recruiting.